Positive.

From GlobeNewswire: 2024-08-05 07:00:00

Axsome Therapeutics, Inc. (NASDAQ: AXSM) reported robust second quarter financial results, with net product revenue reaching $87.2 million, an 87% year-over-year growth. Auvelity® net product sales saw a 135% increase from last year at $65.0 million, while Sunosi® net product revenue rose by 16% to $22.1 million. The company also announced the resubmission of the NDA for AXS-07 in migraine and the initiation of new trials for solriamfetol in various indications.

Second Quarter 2024 Financial Highlights show a successful quarter for Axsome Therapeutics, with total net product revenue of $87.2 million, representing an 87% year-over-year growth. Auvelity® net product sales achieved $65.0 million, a significant increase of 135% compared to last year. Sunosi® net product revenue also increased by 16% to $22.1 million. The company is seeing positive growth in its product revenue across the board.



Read more at GlobeNewswire:: Axsome Therapeutics Reports Second Quarter 2024 Financial